PAREXEL and Osaka International Cancer Institute Form Alliance to Advance Clinical Research in Japan

Alliance to drive greater efficiencies across clinical trials in oncology and hematologyBOSTON and OSAKA, August 21, 2017 – PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, and Osaka International Cancer Institute today announced that they have formed an alliance to advance clinical development in Japan. The partnership will aim to drive greater efficiencies in support of patient recruitment for clinical trials in oncology and hematology, accelerating the development of innovative and effective... Source: RealWire

Read More